Viking Therapeutics is focused on the development of novel therapies for metabolic and endocrine disorders. The company’s research and development activities leverage its expertise in metabolism, and the firm has exclusive worldwide rights to a portfolio of therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.